1. Home
  2. WDC vs ILMN Comparison

WDC vs ILMN Comparison

Compare WDC & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Digital Corporation

WDC

Western Digital Corporation

N/A

Current Price

$174.31

Market Cap

41.3B

Sector

Technology

ML Signal

N/A

Logo Illumina Inc.

ILMN

Illumina Inc.

N/A

Current Price

$134.79

Market Cap

18.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WDC
ILMN
Founded
1970
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.3B
18.9B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
WDC
ILMN
Price
$174.31
$134.79
Analyst Decision
Buy
Hold
Analyst Count
24
15
Target Price
$149.17
$114.93
AVG Volume (30 Days)
7.4M
1.6M
Earning Date
01-28-2026
10-30-2025
Dividend Yield
0.28%
N/A
EPS Growth
578.01
N/A
EPS
6.90
4.46
Revenue
$10,126,000,000.00
$4,288,000,000.00
Revenue This Year
$24.25
N/A
Revenue Next Year
$12.58
$2.08
P/E Ratio
$25.56
$30.24
Revenue Growth
75.22
N/A
52 Week Low
$28.83
$68.70
52 Week High
$188.77
$153.06

Technical Indicators

Market Signals
Indicator
WDC
ILMN
Relative Strength Index (RSI) 59.73 67.48
Support Level $170.02 $132.70
Resistance Level $188.77 $137.09
Average True Range (ATR) 9.00 3.23
MACD 0.49 -0.11
Stochastic Oscillator 64.62 77.96

Price Performance

Historical Comparison
WDC
ILMN

About WDC Western Digital Corporation

Western Digital is a leading vertically integrated supplier of hard disk drives. The HDD market is a practical duopoly, with Western Digital and Seagate being the two largest players. Western Digital designs and manufactures its HDDs, with much of the manufacturing and workforce located in Asia. The primary consumers of HDDs are data centers.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: